Isis Pharmaceuticals Inc., of Carlsbad, Calif., reported Phase I results showing that its ISIS-APOCIIIRx treatment produced rapid, dose-dependent reductions of up to 78 percent in apolipoprotein C-III protein and up to 44 percent in blood triglyceride levels in healthy volunteers. The drug, which targets the apoC-III gene, also was found to be safe and well tolerated. Data were presented at the Cold Spring Harbor Laboratory RNA Therapeutics meeting in New York.